aprocitentan 12.5 MG Oral Tablet [Tryvio]
aprocitentan
RxCUI: 2679070
What the CMS Formulary Data Shows for aprocitentan 12.5 MG Oral Tablet [Tryvio]
Per the CMS 2026 Part D formulary file, aprocitentan 12.5 MG Oral Tablet [Tryvio] (RxNorm concept RXCUI 2679070, generic name aprocitentan) appears on 5 distinct formulary files spanning 7 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 4, with a cross-plan average of Tier 2.8.
Real-world access to aprocitentan 12.5 MG Oral Tablet [Tryvio] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 20% apply quantity limits.
Medicare Part D spending dashboard figures are not published for this drug. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry aprocitentan 12.5 MG Oral Tablet [Tryvio] today.
Coverage Details
- Formularies covering
- 5
- Plans covering
- 7
- Coverage rate
- 0.1%
- Tier range
- Tier 1 – Tier 4
- Average tier
- Tier 3, Preferred Brand
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 20% of formularies
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering aprocitentan 12.5 MG Oral Tablet [Tryvio]
7 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Mass General Brigham SCO (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | Yes | $0 | MA |
| Mass General Brigham One Care (HMO D-SNP) | MASS GENERAL BRIGHAM HEALTH PLAN, INC | T1 | Yes | $0 | MA |
| Mass General Brigham Advantage (PPO) | Mass General Brigham Health Plan, Inc. | T4 | Yes | $0 | MA |
| CareOregon Advantage Plus (HMO D-SNP) | HEALTH PLAN OF CAREOREGON, INC. | T4 | Yes | $0 | OR |
| Mass General Brigham Advantage Secure (HMO-POS) | Mass General Brigham Health Plan, Inc. | T4 | Yes | $62.00 | MA |
| Mass General Brigham Advantage Premier (PPO) | Mass General Brigham Health Plan, Inc. | T4 | Yes | $79.70 | MA |
| Mass General Brigham Advantage Signature (PPO) | Mass General Brigham Health Plan, Inc. | T4 | Yes | $147.20 | MA |
Frequently Asked Questions
Is aprocitentan 12.5 MG Oral Tablet [Tryvio] covered by Medicare Part D?
Yes, aprocitentan 12.5 MG Oral Tablet [Tryvio] is covered by 7 Medicare Part D plans (0.1% of all Part D formularies).
What tier is aprocitentan 12.5 MG Oral Tablet [Tryvio] on Medicare Part D plans?
aprocitentan 12.5 MG Oral Tablet [Tryvio] averages Tier 2.8 across Part D plans, ranging from Tier 1 to Tier 4.
Does aprocitentan 12.5 MG Oral Tablet [Tryvio] require prior authorization?
100% of Part D formularies require prior authorization for aprocitentan 12.5 MG Oral Tablet [Tryvio]. Step therapy: 0%. Quantity limits: 20%.
Read our methodology - how this data is sourced, computed, and verified.